Financial Performance - The company's operating revenue for the first half of 2023 was ¥382,296,115.54, a decrease of 6.73% compared to ¥409,882,118.63 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was a loss of ¥3,851,079.76, representing a decline of 128.84% from a profit of ¥13,354,733.15 in the previous year[23]. - The net cash flow from operating activities decreased by 63.39%, amounting to ¥26,332,736.69 compared to ¥71,921,998.54 in the same period last year[23]. - The basic earnings per share were -¥0.02, down 133.33% from ¥0.06 in the previous year[23]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, with a loss of ¥10,123,570.95 compared to a profit of ¥13,327,383.01 in the same period last year, a decrease of 175.96%[23]. - The weighted average return on net assets was -0.51%, down from 1.73% in the previous year[23]. - The gross profit margin for the overall business was 16.29%, down 5.02% from the previous year[69]. - The revenue from photoinitiators decreased by 35.21% to CNY 80,233,635.39, with a gross margin decline of 18.72%[69]. - The revenue from thiol compounds and derivatives increased by 9.36% to CNY 297,848,255.25, with a gross margin of 22.61%[69]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,395,698,543.56, reflecting a slight increase of 0.45% from ¥1,389,429,540.68 at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company increased by 0.97%, reaching ¥764,613,853.93 compared to ¥757,290,472.85 at the end of the previous year[23]. - Long-term borrowings decreased by 69.52% to CNY 64,000,000.00 from CNY 210,000,000.00, reflecting a reduction in long-term debt[72]. - Total liabilities amounted to CNY 631,084,689.63, showing a slight decrease from CNY 632,139,067.83 year-on-year[173]. - The company's cash and cash equivalents reached CNY 100,443,735.60, compared to CNY 96,661,841.63 at the start of the year, marking a growth of approximately 3.9%[168]. Market and Industry Insights - The company primarily engages in the research, production, and sales of photoinitiators and thiol compounds, establishing itself as a major supplier in the global market[30]. - The radiation curing industry has seen continuous growth since 2016, with increasing applications in semiconductor, display, and communication sectors, despite recent economic uncertainties[31]. - The global 3D printing market is projected to grow at a maximum rate of 23.7% from 2023 to 2025, with a market size expected to exceed $37 billion by 2026[38]. - The pharmaceutical market in China is expected to reach 2.3 trillion RMB by 2025, with a compound annual growth rate (CAGR) of 7.20% from 2021 to 2025[42]. - The market size of China's pharmaceutical intermediates is projected to exceed 290 billion RMB by 2026[42]. Research and Development - The company is focusing on the research and development of phosphorus-containing fine chemicals, particularly in sustainable and low-carbon manufacturing technologies[52]. - The company is committed to enhancing its R&D capabilities to maintain competitive advantages in the face of rapid technological changes[91]. - Research and development expenses decreased by 14.37% to CNY 20,110,597.39 from CNY 23,486,151.41, mainly due to reduced direct investment in R&D[68]. Environmental and Safety Compliance - The company emphasizes safety and environmental protection, adhering to relevant laws and regulations, and promoting clean production and green processes across its manufacturing bases[60][61]. - The company has established a self-monitoring plan for environmental emissions, publicly disclosing relevant pollutant discharge data in compliance with national regulations[116]. - The company reported a total wastewater discharge of 52.2 tons for COD, with a concentration of 154.60 mg/l, which is below the standard[111]. - The company has faced administrative penalties for environmental violations, including a fine of CNY 40,000 for improper storage of high-concentration organic wastewater[119]. Corporate Governance and Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the first half of 2023[105]. - The annual shareholders' meeting had a participation ratio of 44.72% on May 18, 2023[103]. - The company has no stock incentive plans or employee stock ownership plans in place during the reporting period[106]. - The largest shareholder, Zhejiang Yangfan Holdings, holds 22.04% of the shares, totaling 51,729,200, with a decrease of 3,877,000 shares during the reporting period[154]. Risk Management - The company faces risks from a downturn in global macroeconomic conditions, which may lead to reduced demand in downstream markets[90]. - The company has implemented measures to mitigate risks associated with rising labor costs, including improving incentive systems and enhancing automation[93]. - The company has reduced its accounts receivable compared to the previous year, but remains vigilant against potential bad debt risks due to economic slowdowns[97]. Future Outlook - The company anticipates that the radiation curing industry will continue to expand, driven by environmental regulations and technological advancements[33]. - The company is actively expanding its market presence and exploring new channels to diversify risks amid fluctuating market demands[90].

证券代码：300637 证券简称：扬帆新材 公告编号：2023-032 浙江扬帆新材料股份有限公司 第四届董事会第九次会议决议公告 浙江扬帆新材料股份有限公司董事会 2023 年 8 月 28 日 浙江扬帆新材料股份有限公司第四届董事会第九次会议于 2023 年 8 月 24 日 上午在杭州市滨江区信诚路 31 号扬帆大厦五楼会议室召开。公司已于会议召开 48 小时前以通讯方式通知全体董事。会议应出席董事 7 名，实际出席董事 7 名。 会议召开符合《中华人民共和国公司法》、《公司章程》及相关法律法规和规范性 文件的规定。 本次会议由董事长召集，由董事会秘书主持。审议通过如下议案： 一、审议通过《关于<2023 年半年度报告全文及其摘要>的议案》 公司《2023 年半年度报告全文及其摘要》的内容、格式、编制程序符合公 司的实际经营状况和相关法律、法规、规章制度的规定，编制期间未出现违反相 关法律、法规、规章制度和损害公司全体股东利益的情形，真实反映了公司 2023 年上半年度的实际情况。 表决结果：7 票同意，0 票反对，0 票弃权；获全体董事一致通过。 详见同日刊登在中国证监会指定创业板信息披露网站巨潮资讯 ...

浙江扬帆新材料股份有限公司 浙江扬帆新材料股份有限公司独立董事 关于第四届董事会第九次会议相关事项发表的独立意见 二、关于公司对外担保情况的独立意见 经审核，截至 2023 年 6 月 30 日，公司不存在为控股股东及其他关联方、任 何非法人单位或个人提供担保的情况，也无任何除子公司外的对外担保事项，公 司当期和累计为控股股东及其关联方提供担保金额为零。 作为浙江扬帆新材料股份有限公司（以下简称"公司"）的独立董事，我们参 加了公司 2023 年 8月 24 日召开的第四届董事会第九次会议，依据中国证监会《上 市公司独立董事规则》、《深圳证券交易所创业板股票上市规则》等相关法律、法 规和《公司章程》、《公司独立董事工作制度》的有关规定，我们认真履行独立董 事的工作职责，现就相关审议事项发表独立意见如下： 一、关于控股股东及其他关联方占用公司资金情况的独立意见 经审核，公司不存在控股股东及其他关联方非经营性占用公司资金的情况， 也不存在以前年度发生并累计至 2023 年 6 月 30 日的关联方违规占用资金情况。 独立董事：苏为科、张福利、黄法 2023年8月28日 ...

浙江扬帆新材料股份有限公司 第四届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300637 证券简称：扬帆新材 公告编号：2023-033 浙江扬帆新材料股份有限公司监事会 2023 年 8 月 28 日 经监事会审核公司《2023 年半年度报告全文及其摘要》的内容、格式、编 制程序符合公司的实际经营状况和相关法律、法规、规章制度的规定，报告真实 反映了公司 2023 年上半年度的实际情况，不存在任何虚假记载、误导性陈述或 者重大遗漏。 表决结果：3 票同意，0 票反对，0 票弃权；获全体监事一致通过。 详见同日刊登在中国证监会指定创业板信息披露网站巨潮资讯网上的相关 公告。 特此公告。 浙江扬帆新材料股份有限公司第四届监事会第八次会议于 2023 年 8 月 24 日下午在浙江省杭州市滨江区信诚路 31 号扬帆大厦 5 楼会议室召开。公司已于 会议召开 48 小时前以通讯方式通知全体监事。会议应出席监事 3 名，实际出席 监事 3 名。会议召开符合《中华人民共和国公司法》、《公司章程》及相关法律法 规和规范性文件的规定 ...

Group 1: Financial Performance - The company reported a loss in Q1 2023 due to weak downstream demand, global inflation, geopolitical conflicts, and a decline in order volume compared to the previous year [1] - The average product prices have significantly decreased compared to the same period last year, impacting profitability [1] - The company is adjusting its production capacity structure in Inner Mongolia, with some products entering trial production, which has not yet effectively released capacity [1] Group 2: Business Strategy and Development - The company aims to become a leading supplier of light-curing new materials and application system solutions, focusing on the development of new photoinitiators and sulfur-containing fine chemicals [2] - The strategic plan includes three main areas: developing new photoinitiator products, innovating synthesis techniques in sulfur fine chemicals, and focusing on phosphorus-containing intermediates [2] - The company is actively expanding its upstream and downstream supply chains to achieve win-win cooperation [2] Group 3: Market Conditions and Risks - The radiation curing industry is currently in a cyclical downturn, with weak downstream demand affecting the company's photoinitiator business in the short term [3] - The company faces various risks, including macroeconomic and policy risks, production project risks, technological innovation risks, and raw material price fluctuations [3] - The export revenue accounted for 20%-30% of the company's total revenue in the past two years, but has decreased due to global economic downturns and geopolitical issues [3] Group 4: Operational Adjustments - The company is implementing measures to manage raw material cost fluctuations by adjusting production based on historical price trends and optimizing inventory levels [3] - The Inner Mongolia production capacity has not been effectively released due to weak downstream demand, but the company plans to rationally adjust its overall capacity structure [3] - The company is committed to improving production efficiency and reducing unit production costs to support global marketing and business expansion [3]

Financial Performance - The company's revenue for Q1 2023 was ¥158,164,544.68, a decrease of 31.54% compared to ¥231,037,818.81 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥15,037,349.28, representing a decline of 229.47% from a profit of ¥11,614,748.46 in the previous year[5] - Basic and diluted earnings per share were both negative at ¥-0.0641, down 229.49% from ¥0.0495 in the previous year[5] - Total operating revenue for Q1 2023 was ¥158,164,544.68, a decrease of 31.5% compared to ¥231,037,818.81 in Q1 2022[21] - Net profit for Q1 2023 was a loss of ¥15,037,349.28, compared to a profit of ¥11,614,748.46 in Q1 2022[23] - Basic and diluted earnings per share for Q1 2023 were both -¥0.0641, compared to ¥0.0495 in Q1 2022[24] Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥6,725,878.10, a decrease of 122.22% compared to ¥30,266,165.35 in the same period last year[5] - Operating cash flow for the current period was -6,725,878.10, a decrease from 30,266,165.35 in the previous period, indicating a significant decline in operational performance[25] - Cash inflow from operating activities totaled 124,376,654.05, down 38% from 200,465,190.32 in the previous period[25] - Cash outflow from operating activities increased to 131,102,532.15, compared to 170,199,024.97 in the previous period, reflecting a tighter cash management[25] - The ending cash and cash equivalents balance was 76,740,907.40, down from 86,043,976.30 in the previous period, indicating a decrease in liquidity[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,407,873,446.26, an increase of 1.33% from ¥1,389,429,540.68 at the end of the previous year[5] - The company's total liabilities increased to ¥657,377,892.29 in Q1 2023 from ¥632,139,067.83 in Q1 2022, reflecting a rise of 4.0%[20] - The total equity attributable to shareholders decreased to ¥750,495,553.97 in Q1 2023 from ¥757,290,472.85 in Q1 2022, a decline of 0.9%[20] - The company's total liabilities increased, with current liabilities due within one year rising by 72.47% to ¥45,460,133.07[11] Operational Performance - The company's operating income decreased primarily due to a decline in the price and sales volume of photoinitiators[11] - The company reported a 38.08% decrease in cash received from sales of goods and services, totaling ¥116,123,483.59 compared to ¥187,553,033.14 in the previous year[12] - The company experienced a decline in orders and product prices due to global inflation and market competition, leading to a loss in Q1 2023[15] Other Income and Expenses - Other income increased significantly by 550.40% to ¥1,919,557.33, mainly due to an increase in government subsidies[12] - Research and development expenses for Q1 2023 were ¥10,335,803.87, down 15.6% from ¥12,251,077.27 in Q1 2022[21] - The company reported a credit impairment loss of ¥333,153.53 in Q1 2023, compared to a loss of ¥349,281.41 in Q1 2022[23] - Other comprehensive income after tax for Q1 2023 was ¥8,132,709.38, compared to a loss of ¥14,163,707.34 in Q1 2022[23] Market Outlook - The company is adjusting its production capacity based on market demand, with some products entering trial production[15] - The company anticipates a recovery in the downstream market supported by domestic and international trade openings and government policies[15]

浙江扬帆新材料股份有限公司2022年年度报告全文 浙江扬帆新材料股份有限公司 2022 年年度报告 【披露时间】 ...

一、说明会类型 证券代码：300637 证券简称：扬帆新材 公告编号：2023-016 浙江扬帆新材料股份有限公司 关于举行 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示： 1、投资者可于 2023 年 4 月 28 日（星期五）15:00-17:00 访问业绩说明会页面 https://eseb.cn/140Mmm496Ok 在线参与，公司将及时回答投资者的提问。 2、投资者可于 2023 年 4 月 28 日（星期五）15:00 前将需要了解的情况和有关问 题预先通过电子邮件的形式发送至公司投资者关系邮箱，公司将会在说明会上对 投资者普遍关注的问题进行回答。 3、投资者可于 2023 年 4 月 28 日（星期五）15:00-17:00 通过扫描下方小程序码， 点击"进入会议"进行提问。公司将在本次说明会上，在信息披露允许范围内对 投资者普遍关注的问题进行重点回答。 本次说明会采用网络远程的方式举行，公司将针对 2022 年度的经营成果及 财务指标等具体情况与投资者互动交流，在信息披露规则允许的范围内就投资者 普 ...

证券代码：300637 证券简称：扬帆新材 编号：2017-1108-01 | --- | --- | --- | |----------------|-------------------------------|----------------------------------------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | 投资者关系 | □ 新闻发布会 □路演活动 | | | 活动类别 | □ 现场参观 | | | | █ 其他 （机构调研） | | | 参与单位名称及 | 西南证券：黄景文； | | | 人员姓名（排名 | 东方证券资管：郭哲； | | | | 国联证券：吴程浩； | | | 不分大小前后） | 海通证券：刘海荣； | | | 时间 | 2017 年 11 月 08 | 日上午 9:30 至 11:30 | | 地点 | | 浙江省绍兴市杭州湾上虞经济技术开发区纬三路 25 号公司 | | | 会议室 | | | | 副总经理兼董事会秘书:李耀土； | | | 上市公司 ...

证券代码：300637 证券简称：扬帆新材 浙江扬帆新材料股份有限公司投资者关系活动记录表 编号：2018-002 | --- | --- | --- | |----------------|----------------------------|--------------------------------------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系 | □ 新闻发布会 □路演活动 | | | 活动类别 | □现场参观 | | | | █ 其他 （机构调研） | | | 参与单位名称及 | 国泰君安证券 杨思远； | | | 人员姓名（排名 | 中泰证券 李海勇； | | | | 大成基金 韩创； | | | 不分大小前后） | 中融基金 寇文红； | | | 时间 | 14:00-15:15 | | | 地点 | 浙江省杭州市滨江区信诚路 | 31 号扬帆大厦 5 楼会议室 | | 上市公司接待 | 董事会秘书 樊相东； | | | 人员姓名 | 证券部 叶立群； | | | ...